Krystal Biotech (KRYS) Cost of Revenue (2023 - 2026)

Krystal Biotech has disclosed Cost of Revenue across 4 years of filings, most recently posting $6.3 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $6.3 million, up 25.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.3 million (up 7.38% YoY), and the FY2025 annual result was $23.0 million, up 14.89% from the prior year.
• Cost of Revenue came in at $6.3 million for Q1 2026 at Krystal Biotech, down from $6.6 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $7.2 million in Q2 2025 to a low of $223000.0 in Q3 2023.
• The 4-year median for Cost of Revenue is $5.0 million (2025), against an average of $4.8 million.
• Across the five-year window, Cost of Revenue surged 2897.31% in 2024 and sank 36.22% in 2025, its largest moves.
• Krystal Biotech's Cost of Revenue stood at $2.9 million in 2023, then soared by 72.38% to $4.9 million in 2024, then soared by 33.2% to $6.6 million in 2025, then retreated by 4.08% to $6.3 million in 2026.
• The last three Cost of Revenue figures came in at $6.3 million (Q1 2026), $6.6 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.